NEW YORK (GenomeWeb News) - NimbleGen has filed for an initial public offering with the Securities and Exchange Commission, the company said Friday.
The number and prices of shares have not yet been determined.
NimbleGen is a microarray developer that specializes in products and services for comparative genomic hybridization, chromatin immunoprecipitation arrays, comparative genome sequencing, and expression analysis.
J.P. Morgan will serve as bookrunner for the offering, Thomas Weisel Partners will be co-lead manager, and Leerink-Swan and Robert W. Baird are acting co-managers.
NimbleGen has signed several agreements to secure fundamental array IP over the last six months. Last October, the company licensed the rights to Affymetrix’s microarray patents, and in January it licensed rights to Oxford Gene Technology’s patents.